Beta-lactam antibiotic
ApprovedSmall molecule
Beta-lactam antibiotic is one of 35 small molecule programs targeting Mastitis. It is currently in Approved.
2
Indications
5
Total Trials
3
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Beta-lactam antibiotic
UUniversity Hospital, Ghent
Approved
Onglyza
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Advil
KKenvue Brands
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Serevent
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beta-lactam antibiotic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Ghent